Skip to Content
NorthShore is part of Endeavor Health Learn more ›

Dermatology

Home » Dermatology » Research » Clinical Trials

Clinical Trials

Alopecia Areata
Aim: This new clinical trial is studying how to treat patients with alopecia areata with an oral medication. A Phase 2B/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-06651600 in Adult and Adolescent Alopecia Areata Subjects with 50% or Greater Scalp Hair Loss as well as an open label multi-center, long- term study investigating the safety and efficacy of PF-06651600 in adult and adolescent participants with alopecia areata of 25% or more hair loss.

  • Patients must be 12 years and older
  • Patient must have 25% or more hair loss
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Alopecia Areata
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH19-013 and EH19-267
Sponsor: Pfizer
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line "Dermatology Alopecia Areata Clinical Trial"
Open to Enrollment: Yes

Hidradenitis Suppurativa
Aim: This new clinical trial is a randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous injections of secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa

  • Patients must be 18 years and older
  • Patient must have 5 or more active draining lesions of HS in two anatomical body locations
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Hidradenitis Suppurativa
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH19-193
Sponsor: Novartis
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line "Dermatology Hidradenitis Suppurativa Clinical Trial"
Open to Enrollment: Yes

Hidradenitis Suppurativa
Aim: This new clinical trial is a randomized, double-blind, placebo-controlled, phase 2 study to evaluate upadacitinib in study participants with moderate to severe hidradenitis suppurativa

  • Patients must be 18 years and older
  • Patient must have 5 or more active draining lesions of HS in two anatomical body locations
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Hidradenitis Suppurativa
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH20-241
Sponsor: AbbVie
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Hidradenitis Suppurativa Clinical Trial"
Open to Enrollment: Not yet

Hidradenitis Suppurativa
Aim: This new clinical trial is a phase 3, randomized, placebo controlled multicenter study evaluating the efficacy and safety of Bimekizumab in study participants with moderate to severe hidradenitis suppurativa.

  • Patients must be 18 years and older
  • Patient must have 5 or more active draining lesions of HS in two anatomical body locations
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Hidradenitis Suppurativa
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH20-108
Sponsor: UCB
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line "Dermatology Hidradenitis Suppurativa Clinical Trial"
Open to Enrollment: Not yet

Hidradenitis Suppurativa
Aim: This new clinical trial is a phase 3, randomized, placebo controlled multicenter study evaluating the efficacy and safety of Bimekizumab in study participants with moderate to severe hidradenitis suppurativa.

  • Patients must be 18 years and older
  • Patient must have 5 or more active draining lesions of HS in two anatomical body locations
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Hidradenitis Suppurativa
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH19-353
Sponsor: Pfizer
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line "Dermatology Hidradenitis Suppurativa Clinical Trial"
Open to Enrollment:Yes

Atopic Dermatitis/Eczema
Aim:: This new study is a prospective, observational, and longitudinal study in pediatric patients with moderate to severe atopic dermatitis

  • Patients must be younger than 12 years old
  • Patient must have moderate to severe atopic dermatitis
  • Patients must have the ability to make multiple office visits over the course of the study

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Joel Joyce, MD
IRB Approval Number: EH20-204 and EH20-205
Sponsor: Sanofi
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Eczema Clinical Trial"
Open to Enrollment: Not yet

Atopic Dermatitis/Eczema
Aim:: This new clinical trial is a phase 3 pivotal and open label extension to assess the efficacy and safety of injectable Nemolizumab in moderate to severe atopic dermatitis subjects and associated pruritus.

  • Patients must be 18 years and older
  • Patient must have a diagnosis of at least 6 months of eczema or atopic dermatitis in the past 6 months, 10% body surface of covered eczema and tried and failed past treatments.
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Joel Joyce, MD
IRB Approval Number: EH19-265 and EH20-211
Sponsor: Galderma
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Eczema Clinical Trial"
Open to Enrollment: Yes

Atopic Dermatitis/Eczema
Aim: This new clinical trial is a randomized double-blind, placebo controlled efficacy study of oral Nerokinin-1 Receptor Antagonist VLY-686 in patients with atopic dermatitis

  • Patients must be 18 years and older
  • Patient must have a diagnosis of eczema with the pruritus/itch component.
  • Tried and failed previous topical medications
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH20-041
Sponsor: Vanda
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line "Dermatology Eczema Clinical Trial"
Open to Enrollment: Currently paused

Atopic Dermatitis/Eczema
Aim: This new clinical trial is a phase 3 randomized placebo-controlled, double-blind study to evaluate upadacitinib in combination with topical corticosteroids in adolescent subjects with moderate to severe atopic dermatitis.

  • Patients must be 12-18 years old
  • Patient must have a diagnosis of at least 6 months of eczema or atopic dermatitis in the past 6 months, 10% body surface of covered eczema and tried and failed past treatments.
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Joel Joyce, MD
IRB Approval Number: EH18-317
Sponsor: AbbVie
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Eczema Clinical Trial"
Open to Enrollment: Yes

Atopic Dermatitis/Eczema
Aim: This new clinical trial is a phase 3 randomized placebo-controlled, double-blind study to evaluate upadacitinib in adolescent subjects with moderate to severe atopic dermatitis.

  • Patients must be 12-18 years old
  • Patient must have a diagnosis of at least 6 months of eczema or atopic dermatitis in the past 6 months, 10% body surface of covered eczema and tried and failed past treatments.
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Joel Joyce, MD
IRB Approval Number: EH18-293
Sponsor: AbbVie
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Eczema Clinical Trial"
Open to Enrollment: Yes

Atopic Dermatitis/Eczema
Aim:: This new clinical trial is a phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab in patients with moderate to severe atopic dermatitis

  • Patients must be 12 years and older
  • Patient must have a diagnosis of at least 1 year of eczema or atopic dermatitis in the past 6 months, 10% body surface of covered eczema and tried and failed past treatments.
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Joel Joyce, MD
IRB Approval Number: EH20-203
Sponsor: Dermira
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Eczema Clinical Trial"
Open to Enrollment: Not yet